Deutsche Bank starts Medline with a Hold, $40 price target

As previously reported, Deutsche Bank initiated coverage of Medline (MDLN) with a Hold rating and $40 price target Historically, growth has been the best segment within healthcare investing and when distilling the durability of growth down to the simplest answer “it’s all about the moat,” the analyst tells investors in its initiation of Medline.